Alpha-bisabolene is a sesquiterpene hydrocarbon documented in the AromaForge archive from green perilla and related essential-oil chemotypes. The reviewed evidence is strongest for identity and biosynthesis: public databases define the compound, archive records place it in green perilla oil, and plant biochemistry studies characterize alpha-bisabolene synthase enzymes that produce it from farnesyl diphosphate as part of terpene-defense chemistry. No human clinical studies or constituent-specific dermal limits were located in the reviewed public sources.
Chemical identity and composition
PubChem lists alpha-bisabolene with molecular formula C15H24 and a cyclohexene-based sesquiterpene hydrocarbon structure. In the archive's perilla-green oil record, cis-alpha-bisabolene is reported at 5.00-15.00%, and the compound also appears in several other archive oil records as a minor to moderate sesquiterpene marker depending on species and chemotype.
Aroma and practical use
- Use the recorded woody, terpenic, warm descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
ginkgo biosynthesis
A Plant Mol Biol abstract reported that recombinant GbTPS2 from Ginkgo biloba functioned as a bisabolene synthase, establishing alpha-bisabolene production from a defined terpene-synthase gene.
Measured: enzyme product identity
This experimental finding does not establish benefit, dose or safety in people using this blend.
grand fir defense biosynthesis
A PNAS abstract reported that a wound-induced grand fir cDNA encoded an enzyme that produced (E)-alpha-bisabolene as the sole product from farnesyl diphosphate, and the authors interpreted the pathway as part of a defense response against insect herbivores and possibly fungal pathogens.
Measured: sole product formation and defense-context interpretation
This experimental finding does not establish benefit, dose or safety in people using this blend.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
No numeric constituent-specific use limit is available here. Missing is not an unrestricted-use clearance.
No constituent-specific IFRA leave-on limit, dermal sensitization threshold, or phototoxic restriction was located in the reviewed public sources for isolated alpha-bisabolene.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
The reviewed evidence base is mainly chemical and biosynthetic rather than human safety or therapeutic literature.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
No constituent-pair interaction is recorded for this identity. The report does not assume either amplification or incompatibility.
How the effects were investigated
farnesyl diphosphate cyclization
BRENDA and primary enzyme papers describe alpha-bisabolene synthase as converting farnesyl diphosphate to (E)-alpha-bisabolene, with Mg2+ or Mn2+ support typical of terpene synthases.
This experimental finding does not establish benefit, dose or safety in people using this blend.
wound inducible conifer defense signal
In grand fir, alpha-bisabolene synthase expression was reported as wound inducible, and the product was interpreted as part of a terpenoid defense response aimed at insect herbivores and possibly fungal pathogens.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- No human clinical studies specific to isolated alpha-bisabolene were located in the reviewed public sources.
- No constituent-specific dermal-limit, sensitization, or phototoxicity data were located in the reviewed public sources.
- Accessible evidence for alpha-bisabolene is dominated by plant biochemistry and occurrence data rather than direct isolated-compound pharmacology.
- No constituent-specific numeric dermal reference is available here.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.